{"pmid":32474009,"title":"COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities.","text":["COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities.","The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best approach in controlling disease spread. In this review, current therapeutic options, preventive methods and transmission routes of COVID-19 are discussed.","Clin Chim Acta","Lotfi, Melika","Hamblin, Michael R","Rezaei, Nima","32474009"],"abstract":["The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best approach in controlling disease spread. In this review, current therapeutic options, preventive methods and transmission routes of COVID-19 are discussed."],"journal":"Clin Chim Acta","authors":["Lotfi, Melika","Hamblin, Michael R","Rezaei, Nima"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474009","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.cca.2020.05.044","keywords":["covid-19","prevention","sars-cov-2","transmission","treatment"],"topics":["Treatment","Transmission","Prevention"],"weight":1,"_version_":1668341932636504064,"score":9.490897,"similar":[{"pmid":32454187,"title":"Review of trials currently testing treatment and prevention of COVID-19.","text":["Review of trials currently testing treatment and prevention of COVID-19.","BACKGROUND: As COVID-19 cases continue to rise globally, evidence from large randomised controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are undertaken all over the world. OBJECTIVES: We summarised all registered clinical trials examining treatment and prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved studies. DATA SOURCES: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union Clinical Trials Register were systematically searched. STUDY ELIGIBILITY CRITERIA: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. No language, country or study design restrictions were applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative strategies for COVID-19. PARTICIPANTS: and interventions: No restrictions in terms of participants' age and medical background or type of intervention were enforced. METHODS: The registries were searched using the term \"coronavirus\" or \"COVID-19\" from their inception until 26(th) March 2020.Additional manual search of the registries was also performed. Eligible studies were summarised and tabulated. Interventional trials were methodologically analysed, excluding expanded access studies and trials testing Traditional Chinese Medicine. RESULTS: In total, 309 trials evaluating therapeutic management options, 23 studies assessing preventive strategies and 3 studies examining both were retrieved. Finally, 214 studies were methodologically reviewed. Interventional treatment studies were mostly randomised (n=150, 76%) and open-label (n=73, 37%) with a median number of planned inclusions of 90 (IQR 40-200). Major categories of interventions that are currently being investigated are discussed. CONCLUSION: Numerous clinical trials have been registered since the onset of the COVID-19 pandemic. Summarised data on these trials will assist physicians and researchers to promote patient care and guide future research efforts for COVID-19 pandemic containment.","Clin Microbiol Infect","Fragkou, Paraskevi C","Belhadi, Drifa","Peiffer-Smadja, Nathan","Moschopoulos, Charalampos D","Lescure, Francois-Xavier","Janocha, Hannah","Karofylakis, Emmanouil","Yazdanpanah, Yazdan","Mentre, France","Skevaki, Chrysanthi","Laouenan, Cedric","Tsiodras, Sotirios","32454187"],"abstract":["BACKGROUND: As COVID-19 cases continue to rise globally, evidence from large randomised controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are undertaken all over the world. OBJECTIVES: We summarised all registered clinical trials examining treatment and prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved studies. DATA SOURCES: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union Clinical Trials Register were systematically searched. STUDY ELIGIBILITY CRITERIA: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. No language, country or study design restrictions were applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative strategies for COVID-19. PARTICIPANTS: and interventions: No restrictions in terms of participants' age and medical background or type of intervention were enforced. METHODS: The registries were searched using the term \"coronavirus\" or \"COVID-19\" from their inception until 26(th) March 2020.Additional manual search of the registries was also performed. Eligible studies were summarised and tabulated. Interventional trials were methodologically analysed, excluding expanded access studies and trials testing Traditional Chinese Medicine. RESULTS: In total, 309 trials evaluating therapeutic management options, 23 studies assessing preventive strategies and 3 studies examining both were retrieved. Finally, 214 studies were methodologically reviewed. Interventional treatment studies were mostly randomised (n=150, 76%) and open-label (n=73, 37%) with a median number of planned inclusions of 90 (IQR 40-200). Major categories of interventions that are currently being investigated are discussed. CONCLUSION: Numerous clinical trials have been registered since the onset of the COVID-19 pandemic. Summarised data on these trials will assist physicians and researchers to promote patient care and guide future research efforts for COVID-19 pandemic containment."],"journal":"Clin Microbiol Infect","authors":["Fragkou, Paraskevi C","Belhadi, Drifa","Peiffer-Smadja, Nathan","Moschopoulos, Charalampos D","Lescure, Francois-Xavier","Janocha, Hannah","Karofylakis, Emmanouil","Yazdanpanah, Yazdan","Mentre, France","Skevaki, Chrysanthi","Laouenan, Cedric","Tsiodras, Sotirios"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454187","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.cmi.2020.05.019","keywords":["covid-19","sars-cov-2","anti-inflammatory","antivirals","clinical trials","immunomodulators","novel coronavirus","pneumonia","prevention","treatment"],"topics":["Treatment"],"weight":1,"_version_":1667881798415155200,"score":155.0172},{"pmid":32234465,"pmcid":"PMC7118423","title":"Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment.","text":["Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment.","Viral respiratory diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) always pose a severe threat to people. First identified in late December 2019, a novel coronavirus (2019-nCoV; SARS-CoV-2) has affected many provinces in China and multiple countries worldwide. The viral outbreak has aroused panic and a public-health emergency around the world, and the number of infections continues to rise. However, the causes and consequences of the pneumonia remain unknown. To effectively implement epidemic prevention, early identification and diagnosis are critical to disease control. Here we scrutinise a series of available studies by global scientists on the clinical manifestations, detection methods and treatment options for the disease caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19), and also propose potential strategies for preventing the infection.","Int J Antimicrob Agents","Kang, Shuntong","Peng, Wenyao","Zhu, Yuhao","Lu, Shiyao","Zhou, Min","Lin, Wei","Wu, Wenfang","Huang, Shu","Jiang, Liping","Luo, Xuan","Deng, Meichun","32234465"],"abstract":["Viral respiratory diseases such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) always pose a severe threat to people. First identified in late December 2019, a novel coronavirus (2019-nCoV; SARS-CoV-2) has affected many provinces in China and multiple countries worldwide. The viral outbreak has aroused panic and a public-health emergency around the world, and the number of infections continues to rise. However, the causes and consequences of the pneumonia remain unknown. To effectively implement epidemic prevention, early identification and diagnosis are critical to disease control. Here we scrutinise a series of available studies by global scientists on the clinical manifestations, detection methods and treatment options for the disease caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19), and also propose potential strategies for preventing the infection."],"journal":"Int J Antimicrob Agents","authors":["Kang, Shuntong","Peng, Wenyao","Zhu, Yuhao","Lu, Shiyao","Zhou, Min","Lin, Wei","Wu, Wenfang","Huang, Shu","Jiang, Liping","Luo, Xuan","Deng, Meichun"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234465","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105950","keywords":["2019 novel coronavirus","2019-ncov","detection","mechanism","sars-cov-2","treatment"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1666138490267500544,"score":151.03961},{"pmid":32398954,"pmcid":"PMC7211182","title":"Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China.","text":["Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China.","Coronavirus (CoV) has been one of the major pandemic threats to human health in the last two decades. The human coronavirus was first identified in 1960s. CoVs 229E, NL63, OC43, HKU1, SARS-CoV, and MERS-CoV have caused numerous disasters or human deaths worldwide. Recently, an outbreak of the previously unknown deadly CoV disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome CoV 2 (SARS-CoV-2, early named 2019-nCoV) occurred in Wuhan, China, and it had caused 81238 cases of confirmed infection, including 3250 deaths until March 19, 2020. Its risks and pandemic potential have brought global consideration. We summarized epidemiology, virological characteristics, clinical symptoms, diagnostic methods, clinical treatments, and prevention methods for COVID-19 to present a reference for the future wave of probable CoV outbreaks.","Int J Biol Sci","Awadasseid, Annoor","Wu, Yanling","Tanaka, Yoshimasa","Zhang, Wen","32398954"],"abstract":["Coronavirus (CoV) has been one of the major pandemic threats to human health in the last two decades. The human coronavirus was first identified in 1960s. CoVs 229E, NL63, OC43, HKU1, SARS-CoV, and MERS-CoV have caused numerous disasters or human deaths worldwide. Recently, an outbreak of the previously unknown deadly CoV disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome CoV 2 (SARS-CoV-2, early named 2019-nCoV) occurred in Wuhan, China, and it had caused 81238 cases of confirmed infection, including 3250 deaths until March 19, 2020. Its risks and pandemic potential have brought global consideration. We summarized epidemiology, virological characteristics, clinical symptoms, diagnostic methods, clinical treatments, and prevention methods for COVID-19 to present a reference for the future wave of probable CoV outbreaks."],"journal":"Int J Biol Sci","authors":["Awadasseid, Annoor","Wu, Yanling","Tanaka, Yoshimasa","Zhang, Wen"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398954","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.7150/ijbs.45018","keywords":["covid-19","sars-cov-2","infection","prevention","treatment"],"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Transmission","Prevention"],"weight":1,"_version_":1666865855015682048,"score":147.60376},{"pmid":32503820,"title":"Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature.","text":["Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature.","The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in the city of Wuhan in December of 2019 and since then more than 5,000,000 people have been infected, with approximately 338,000 deaths worldwide. The virus causes the coronavirus disease 2019 (COVID-19), which is characterized by fever, myalgia and cough, with severe acute respiratory syndrome being the most fearsome complication. Nevertheless, the vast majority of cases present mild symptoms or none. Central nervous system and cardiovascular manifestations have been reported. The range of ocular manifestations, either as a result of the infection or as a result of the treatment, has not yet been discussed. In this study, a systematic review of current literature relevant to COVID-19 was performed with focus on modes of transmission, ocular manifestations related to infection and medications, as well as the control of infection in ophthalmic practice.","In Vivo","Douglas, Konstantinos A A","Douglas, Vivian Paraskevi","Moschos, Marilita M","32503820"],"abstract":["The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in the city of Wuhan in December of 2019 and since then more than 5,000,000 people have been infected, with approximately 338,000 deaths worldwide. The virus causes the coronavirus disease 2019 (COVID-19), which is characterized by fever, myalgia and cough, with severe acute respiratory syndrome being the most fearsome complication. Nevertheless, the vast majority of cases present mild symptoms or none. Central nervous system and cardiovascular manifestations have been reported. The range of ocular manifestations, either as a result of the infection or as a result of the treatment, has not yet been discussed. In this study, a systematic review of current literature relevant to COVID-19 was performed with focus on modes of transmission, ocular manifestations related to infection and medications, as well as the control of infection in ophthalmic practice."],"journal":"In Vivo","authors":["Douglas, Konstantinos A A","Douglas, Vivian Paraskevi","Moschos, Marilita M"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503820","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21873/invivo.11952","keywords":["covid-19","ocular manifestations","ophthalmology","prevention","review","side-effects","treatment"],"locations":["China","Wuhan","fever","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Transmission","Treatment","Prevention"],"weight":1,"_version_":1668892488288436224,"score":142.43367},{"pmid":32292802,"pmcid":"PMC7138902","title":"Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019-2020.","text":["Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019-2020.","Wuhan, the city in Hubei province in China is in the focus of global community due to the outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), formerly known as 2019-nCoV. The virus emerged in humans from Wuhan seafood market probably via zoonotic transmission. Within a few days the virus spread its tentacles rapidly to neighboring cities in China and to different geographical regions through travelers and to some extent by human to human transmission leading to significant disease burden globally. More than 2,00,000 people (including more than 8000 deaths) have been infected with this respiratory illness across 167 countries and territories worldwide leading to a pandemic. The present review provides an outline about emergence and spread of SARS-CoV-2 from Wuhan, China in 2019-2020. We have also provided information about the classification, genome, proteins, clinical presentation of COVID-19, type of clinical specimens to be collected and diagnostic methods adopted to identify the respiratory illness. In addition we have also provided information about transmission dynamics, prevention measures and treatment options that are available at the present. Subsequently, we have given a comprehensive overview of the spread of this infection from China to the other parts of the globe. Management of the ongoing outbreak of SARS-CoV-2 encompassing surveillance, clinical, immunological, genetic and evolutionary investigations are likely to provide the desired results. Joint efforts of global scientific community are needed at this hour in terms of enhancement of research on development of accurate diagnostics, antiviral therapeutics and finally into formation of an effective vaccine against the emerging novel coronavirus.","Virusdisease","Islam, Arshi","Ahmed, Anwar","Naqvi, Irshad H","Parveen, Shama","32292802"],"abstract":["Wuhan, the city in Hubei province in China is in the focus of global community due to the outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), formerly known as 2019-nCoV. The virus emerged in humans from Wuhan seafood market probably via zoonotic transmission. Within a few days the virus spread its tentacles rapidly to neighboring cities in China and to different geographical regions through travelers and to some extent by human to human transmission leading to significant disease burden globally. More than 2,00,000 people (including more than 8000 deaths) have been infected with this respiratory illness across 167 countries and territories worldwide leading to a pandemic. The present review provides an outline about emergence and spread of SARS-CoV-2 from Wuhan, China in 2019-2020. We have also provided information about the classification, genome, proteins, clinical presentation of COVID-19, type of clinical specimens to be collected and diagnostic methods adopted to identify the respiratory illness. In addition we have also provided information about transmission dynamics, prevention measures and treatment options that are available at the present. Subsequently, we have given a comprehensive overview of the spread of this infection from China to the other parts of the globe. Management of the ongoing outbreak of SARS-CoV-2 encompassing surveillance, clinical, immunological, genetic and evolutionary investigations are likely to provide the desired results. Joint efforts of global scientific community are needed at this hour in terms of enhancement of research on development of accurate diagnostics, antiviral therapeutics and finally into formation of an effective vaccine against the emerging novel coronavirus."],"journal":"Virusdisease","authors":["Islam, Arshi","Ahmed, Anwar","Naqvi, Irshad H","Parveen, Shama"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292802","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13337-020-00575-1","keywords":["covid-19","china","emergence","global transmission","sars-cov-2","wuhan city"],"locations":["Wuhan","Hubei","China","Wuhan","China","Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Transmission","Treatment","Diagnosis"],"weight":1,"_version_":1666138494325489664,"score":141.52415}]}